The Company announced today approval of the First-in-Human (FIH) clinical study of its novel, wearable neuromodulation platform for treating overactive bladder (OAB) in females. The Western IRB (WIRB) approved participation of up to 15 subjects in a study assessing fit, patient placement and safety of the FemPulse device, as well as potential for improvement in symptoms associated with OAB. The first center planned to participate in the study is the University of Washington, where Dr. Suzette Sutherland will serve as primary investigator.
